首页> 外文期刊>Clinical immunology: The official journal of the Clinical Immunology Society >Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy.
【24h】

Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy.

机译:通过基于紫杉醇的化疗对调节性T细胞而非效应T细胞的差异性损伤。

获取原文
获取原文并翻译 | 示例
           

摘要

Characterized as a mitotic inhibitor, paclitaxel has gained importance as a promising agent for the treatment of advanced non-small cell lung cancer (NSCLC). However, whether paclitaxel has immune modulatory effects remains unclear. In this study, we analyzed 55 peripheral blood samples from NSCLC patients who underwent paclitaxel-based chemotherapy. We found that among the lymphocyte subsets, paclitaxel selectively decreased the size of the regulatory T cell (Treg) population rather than other subsets including effector T cells (Teff). Apoptosis by upregulating the expression of the cell death receptor Fas (CD95) contributed to the reduced cell number of Treg. Importantly, the inhibitory function of Treg was significantly impaired, while the production of Th1 cytokines IFN-gamma and IL-2 and the expression of the activation marker CD44 among CD4(+) and CD8(+) T cells were augmented after paclitaxel treatment. These results strongly demonstrated that paclitaxel-based chemotherapy played important rolesin modulating immune responses.
机译:紫杉醇被描述为有丝分裂抑制剂,作为治疗晚期非小细胞肺癌(NSCLC)的有前途的药物已变得越来越重要。但是,紫杉醇是否具有免疫调节作用尚不清楚。在这项研究中,我们分析了55名接受紫杉醇化疗的NSCLC患者的外周血样本。我们发现,在淋巴细胞亚群中,紫杉醇选择性降低了调节性T细胞(Treg)群体的大小,而不是包括效应T细胞(Teff)在内的其他亚群。通过上调细胞死亡受体Fas(CD95)的表达引起的凋亡有助于减少Treg的细胞数量。重要的是,紫杉醇处理后,Treg的抑制功能显着受损,而Th1细胞因子IFN-γ和IL-2的产生以及CD4(+)和CD8(+)T细胞中活化标记CD44的表达增加。这些结果强烈证明基于紫杉醇的化学疗法在调节免疫反应中起重要作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号